HUTCHMED (China) vs Telix Pharmaceuticals
HCM and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and TLX compare
Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −0.89% at Telix Pharmaceuticals.
HUTCHMED (China) scores higher on the StockData Score (5 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | TLX |
|---|---|---|
| Size and price | ||
| Share price | $14.90 | $9.23 |
| Change, 1 year | −2.5% | −5.9% |
| Change, 5 years | −51.5% | – |
| Beta (5Y) | 0.97 | 1.45 |
| Employees | 109 | 1,120 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 55.6% (better) |
| Revenue growth, 5Y average | 19.2% | – |
| Net income growth (TTM) | 1111% (better) | −121% |
| EPS growth (TTM) | 1200% (better) | −122% |
| Profitability | ||
| Gross margin | 38.7% | 53.1% (better) |
| Operating margin | −7.1% | 3.7% (better) |
| Net margin | 83.3% (better) | −0.89% |
| FCF margin | −14.4% | −5.3% (better) |
| Return on equity | 36.7% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Net debt / EBITDA | – | 5.17 |
| Interest coverage | −13.7× | 0.7× (better) |
| Current ratio | 5.64 (better) | 2.01 |
| Piotroski F-score | 4 (better) | 2 |
| Ownership | ||
| Held by institutions | 0.51% | 0.94% |
| Held by insiders | 0.44% | 8.3% |
| Insider net buying, 12 months | – | $1.0M |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- TLX stock overview
- TLX income statement
- TLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.